Singapore's ClavystBio launches Node 1, a collaborative innovation space to foster healthcare partnerships

ClavystBio, a life sciences venture builder, today announced the launch of its collaborative innovation space Node 1 at Singapore Science Park by Deputy Prime Minister Mr Heng Swee Keat.

Node 1 will convene life science communities, fostering collaboration and partnerships among innovators, entrepreneurs and investors across the world to catalyse global human health solutions. Node 1 strengthens ClavystBio’s mission to accelerate the translation of life sciences breakthroughs into human health impact. Its plug-and-play spaces (laboratories and offices) provide accessible infrastructure for new ventures that have graduated from incubators to progress to their next milestones. Node 1 also promotes interaction and collaboration between the public and private sectors by convening discussion panels, workshops and focus groups.

Khoo Shih, Chief Executive Officer of ClavystBio said, “We believe that by connecting people, ideas and resources across geographies, we can launch and grow life sciences companies with global impact. ClavystBio and Node 1 were founded on the recognition that Singapore’s life sciences industry stands at a pivotal juncture, and we must move quickly to translate our scientific innovations and clinical excellence into real world human health solutions.”

Since 2022, ClavystBio has invested in 11 biotech, diagnostics and digital health companies, as well as 3 early-stage venture funds. It has also co-established 65LAB with Evotec and venture capital partners Lightstone Ventures, Leaps by Bayer and Polaris Partners to accelerate drug discovery and venture creation from academic and R&D institutions Agency for Science, Technology and Research (A*STAR), the National University of Singapore and DUKE-NUS Medical School.

ClavystBio is guided by a Board of global life sciences industry leaders and distinguished Advisors. The Board is chaired by Dr Fidah Alsagoff, Joint Head of the Enterprise Development Group (Singapore) and Head of Life Sciences, Temasek; and includes Ken Ehlert, Dr. Ranga Krishnan, Steve Krognes, Dr Vicki Sato, and Amy Schulman. Dr Robert Langer and Dr Amy Abernethy serve as Advisors.